These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26559739)

  • 1. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
    Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker targets and novel therapeutics.
    Clouser M; Hess LM; Chambers SK
    Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin for the treatment of ovarian cancer.
    Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
    Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
    Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
    Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of new molecules in the treatment of advanced thyroid cancer].
    Galofré JC; Gómez-Sáez JM; Álvarez Escola C; Álvarez García E; Anda Apiñaniz E; Calleja A; Donnay S; Lucas-Martin A; Menéndez Torre E; Navarro González E; Pereg V; Pérez Corral B; Santamaría Sandi J; Riesco Eizaguirre G; Zafón Llopis C;
    Endocrinol Nutr; 2011 Oct; 58(8):381-6. PubMed ID: 21924966
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Tian C; Bookman MA
    Gynecol Oncol; 2010 May; 117(2):324-9. PubMed ID: 20185168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Nuñez ER
    Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study.
    Freyer G; Ray-Coquard I; Fischer D; Martín AG; Kielhorn A; Chia V; Nanayakkara N; Taylor A
    Int J Gynecol Cancer; 2016 Feb; 26(2):240-7. PubMed ID: 26745696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
    Smolle E; Taucher V; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.